Cypherpunk Technologies Inc. (CYPH): R&D Expense
$25.67M
Year ended 2025-12-31
$2.58M
Trailing 12 months to 2026-06-30
-17.0%
3-year compound annual growth
+4.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.67M | -55.1% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $57.21M | -21.9% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $73.23M | +62.9% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $44.97M | +39.8% | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | $32.16M | +57.5% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $20.42M | -16.2% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $24.37M | +11.6% | 2021-03-12, From 2019-01-01 |
| 2018-12-31 | $21.83M | -3.0% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $22.50M | -3.4% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $23.29M | n/a | 2018-02-23, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $25.67M | -55.1% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $13.42M | +38.3% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $1.63M | n/a |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $52.65M | +56.7% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $46.71M | +225.8% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $70.09M | +117.5% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $66.27M | +27.5% |
Compare CYPH, RNAZ, APUS, ACRS side by side · Screen every company in Pharmaceutical Preparations ↗